PE20141669A1 - Moduladores selectivos del receptor androgeno - Google Patents

Moduladores selectivos del receptor androgeno

Info

Publication number
PE20141669A1
PE20141669A1 PE2014000521A PE2014000521A PE20141669A1 PE 20141669 A1 PE20141669 A1 PE 20141669A1 PE 2014000521 A PE2014000521 A PE 2014000521A PE 2014000521 A PE2014000521 A PE 2014000521A PE 20141669 A1 PE20141669 A1 PE 20141669A1
Authority
PE
Peru
Prior art keywords
methyl
selective androgen
cyclopentil
benzonitrile
chloro
Prior art date
Application number
PE2014000521A
Other languages
English (en)
Spanish (es)
Inventor
Prabhakar Kondaji Jadhav
Ashraf Saeed
Jonathan Edward Green
Venkatesh Krishnan
Donald Paul Matthews
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47046879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141669(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20141669A1 publication Critical patent/PE20141669A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2014000521A 2011-10-13 2012-10-05 Moduladores selectivos del receptor androgeno PE20141669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161546711P 2011-10-13 2011-10-13

Publications (1)

Publication Number Publication Date
PE20141669A1 true PE20141669A1 (es) 2014-11-08

Family

ID=47046879

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000521A PE20141669A1 (es) 2011-10-13 2012-10-05 Moduladores selectivos del receptor androgeno

Country Status (28)

Country Link
US (1) US8658693B2 (enExample)
EP (1) EP2766350B1 (enExample)
JP (1) JP6002228B2 (enExample)
KR (1) KR20140067102A (enExample)
CN (1) CN103842348B (enExample)
AP (1) AP2014007548A0 (enExample)
AR (1) AR088082A1 (enExample)
AU (1) AU2012321113B2 (enExample)
BR (1) BR112014008668A2 (enExample)
CA (1) CA2847889A1 (enExample)
CL (1) CL2014000895A1 (enExample)
CO (1) CO6910195A2 (enExample)
CR (1) CR20140156A (enExample)
DO (1) DOP2014000075A (enExample)
EA (1) EA201490519A1 (enExample)
EC (1) ECSP14013305A (enExample)
ES (1) ES2626820T3 (enExample)
GT (1) GT201400067A (enExample)
IL (1) IL231440A0 (enExample)
MX (1) MX2014004558A (enExample)
PE (1) PE20141669A1 (enExample)
PH (1) PH12014500808A1 (enExample)
PL (1) PL2766350T3 (enExample)
PT (1) PT2766350T (enExample)
SG (1) SG11201401794YA (enExample)
TN (1) TN2014000136A1 (enExample)
TW (1) TWI449686B (enExample)
WO (1) WO2013055577A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
TW201534586A (zh) * 2013-06-11 2015-09-16 Orion Corp 新穎cyp17抑制劑/抗雄激素劑
JP6457523B2 (ja) 2013-12-04 2019-01-23 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングEvotec International GmbH 医薬組成物のためのスルホキシイミン置換キナゾリン
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CA2944103A1 (en) 2014-05-07 2015-11-12 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
MX389592B (es) 2016-09-02 2025-03-20 Suven Life Sciences Ltd Moduladores alostericos positivos del receptor m1 muscarinico
EP3684761A1 (en) 2017-09-18 2020-07-29 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
AR122725A1 (es) * 2020-06-24 2022-09-28 Celgene Corp Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos
WO2025104624A1 (en) * 2023-11-14 2025-05-22 Pfizer Inc. Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594405A (en) * 1968-05-17 1971-07-20 Du Pont Substituted pyranyl anilines as plant growth modifiers
ES2254611T3 (es) * 2001-05-11 2006-06-16 Pfizer Products Inc. Derivados de tiazol.
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
ATE412647T1 (de) * 2005-05-13 2008-11-15 Lilly Co Eli Substituierte n-arylpyrrolidine als selektive modulatoren des androgenrezeptors
BRPI0619208A2 (pt) * 2005-11-30 2011-09-20 Astellas Pharma Inc derivado de 2-aminobenzamida c07d 307/14 c07d 307/22 c07d 309/14 c07d 319/12 c07d 401/12 c07d 405/12 c07d 413/12 c07d 417/12
CA2684240A1 (en) * 2007-04-16 2008-10-30 Serenex, Inc. Tetrahydroindole and tetrahydroindazole derivatives
US8190467B2 (en) * 2007-10-19 2012-05-29 Michelle Letendre-Hedlund Methods of identifying environmentally friendly businesses or individuals
BRPI0907844B8 (pt) * 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos

Also Published As

Publication number Publication date
CR20140156A (es) 2014-05-16
PH12014500808A1 (en) 2019-07-03
PT2766350T (pt) 2017-05-22
JP2014530818A (ja) 2014-11-20
AU2012321113A1 (en) 2014-03-27
CN103842348A (zh) 2014-06-04
JP6002228B2 (ja) 2016-10-05
WO2013055577A1 (en) 2013-04-18
BR112014008668A2 (pt) 2017-04-25
CO6910195A2 (es) 2014-03-31
EP2766350A1 (en) 2014-08-20
ES2626820T3 (es) 2017-07-26
CA2847889A1 (en) 2013-04-18
AR088082A1 (es) 2014-05-07
TN2014000136A1 (en) 2015-07-01
PL2766350T3 (pl) 2017-08-31
IL231440A0 (en) 2014-04-30
MX2014004558A (es) 2014-08-01
EP2766350B1 (en) 2017-04-05
SG11201401794YA (en) 2014-09-26
ECSP14013305A (es) 2014-05-31
CN103842348B (zh) 2015-08-19
AP2014007548A0 (en) 2014-03-31
TW201329026A (zh) 2013-07-16
CL2014000895A1 (es) 2014-08-22
US8658693B2 (en) 2014-02-25
GT201400067A (es) 2015-02-27
KR20140067102A (ko) 2014-06-03
DOP2014000075A (es) 2014-06-01
US20130217762A1 (en) 2013-08-22
AU2012321113B2 (en) 2015-07-09
EA201490519A1 (ru) 2014-09-30
TWI449686B (zh) 2014-08-21

Similar Documents

Publication Publication Date Title
PE20141669A1 (es) Moduladores selectivos del receptor androgeno
AR125013A2 (es) Método para mejorar la solubilidad de una sustancia que es 9-etil-6,6-dimetil-8-(4-morfolin-4-il-piperidin-1-il)-11-oxo-6,11-dihidro-5h-benzo[b]carbazol-3-carbonitrilo o una sal del mismo
EA201170676A1 (ru) Агонисты рецептора меланокортина
RU2008139315A (ru) Избирательные андрогенные рецепторные модуляторы
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
CR20130307A (es) Composiciones y métodos para modular el fxr
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
CO2022010305A2 (es) Método y aplicación de preparación de compuesto como agente de degradación de proteínas
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
HN2012001351A (es) Derivados de 3- hidroxi-5-arilisotiazol novedosos
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
EA201190021A1 (ru) Модуляторы toll-подобных рецепторов
DOP2013000181A (es) Moduladores del receptor de glucagon
PE20160996A1 (es) Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp
EA201390843A1 (ru) Применение агониста toll-подобного рецептора для лечения рака
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
ECSP11011398A (es) Inhibidores de beta-secretasa
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
EA201291476A1 (ru) Комбинации, содержащие атипичные антипсихотические средства и агонисты taar1
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120

Legal Events

Date Code Title Description
FD Application declared void or lapsed